0000950170-23-071478.txt : 20231219 0000950170-23-071478.hdr.sgml : 20231219 20231219160643 ACCESSION NUMBER: 0000950170-23-071478 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231216 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001856725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40672 FILM NUMBER: 231497341 BUSINESS ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: (408) 457-3700 MAIL ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 8-K 1 rani-20231216.htm 8-K 8-K
false000185672500018567252023-12-162023-12-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2023

 

 

Rani Therapeutics Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40672

86-3114789

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2051 Ringwood Avenue

 

San Jose, California

 

95131

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (408) 457-3700

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

 

RANI

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2023, the Board of Directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) approved a stock option repricing where the exercise price of certain outstanding options to purchase shares of the Company’s Class A common stock (the “Common Stock”) under the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) or the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) was reduced to $2.84 per share, the closing price of the Common Stock on the approval date (the “Option Repricing”). The Option Repricing includes unvested options granted pursuant to both the 2021 Plan and 2016 Plan that are held by employees, including the Company’s named executive officers, consultants, and non-employee members of the Board. No other terms of the options were modified, and the options will continue to vest according to their original vesting schedules and will retain their original expiration dates. After evaluating several alternatives, the Board determined that the Option Repricing, which is permitted under the terms of the 2021 Plan and 2016 Plan, was in the best interests of the Company and its stockholders and provides the most effective means of retaining and incentivizing the Company’s key contributors while preserving cash resources and without incurring stock dilution from significant additional equity grants.

 

The following options held by the Company’s named executive officers were included in the Option Repricing:

Name and Position

 

Option Shares

 

Exercise Price Range of Original Options

Talat Imran

 

936,444

 

$5.44 to $19.56

Chief Executive Officer

 

 

 

 

Svai Sanford

 

313,558

 

$5.44 to $13.21

Chief Financial Officer

 

 

 

 

Mir Hashim

 

328,374

 

$5.44 to $13.21

Chief Scientific Officer

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

Rani Therapeutics Holdings, Inc.

 

 

 

 

Date:

December 19, 2023

By:

/s/ Svai Sanford

 

 

 

Svai Sanford
Chief Financial Officer

 

 EX-101.SCH 2 rani-20231216.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 rani-20231216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 rani-20231216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Dec. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 16, 2023
Entity Registrant Name Rani Therapeutics Holdings, Inc.
Entity Central Index Key 0001856725
Entity Emerging Growth Company true
Entity File Number 001-40672
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 86-3114789
Entity Address, Address Line One 2051 Ringwood Avenue
Entity Address, City or Town San Jose
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95131
City Area Code (408)
Local Phone Number 457-3700
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol RANI
Security Exchange Name NASDAQ
XML 6 rani-20231216_htm.xml IDEA: XBRL DOCUMENT 0001856725 2023-12-16 2023-12-16 false 0001856725 8-K 2023-12-16 Rani Therapeutics Holdings, Inc. DE 001-40672 86-3114789 2051 Ringwood Avenue San Jose CA 95131 (408) 457-3700 N/A false false false false Class A common stock, par value $0.0001 per share RANI NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rani-20231216.htm rani-20231216.xsd rani-20231216_lab.xml rani-20231216_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rani-20231216.htm": { "nsprefix": "rani", "nsuri": "http://www.ranitherapeutics.com/20231216", "dts": { "inline": { "local": [ "rani-20231216.htm" ] }, "schema": { "local": [ "rani-20231216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rani-20231216_lab.xml" ] }, "presentationLink": { "local": [ "rani-20231216_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_91205f4a-dea3-4b80-90dd-f1341e49b287", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rani-20231216.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_91205f4a-dea3-4b80-90dd-f1341e49b287", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rani-20231216.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ranitherapeutics.com/20231216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-23-071478-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-071478-xbrl.zip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end